

August 11, 2026

Listing Department
BSE LIMITED
P J Towers, Dalal Street,
Mumbai-400 001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: ZYDUSLIFE

Sub: **Press Release**

Ref.: **Disclosure under regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Pursuant to the provisions of regulation 30 of the Listing Regulations, please find enclosed the press release dated August 11, 2026, to be published in the newspapers relating to unaudited financial results for the quarter ended on June 30, 2026.

Please find the same in order.

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus Lifesciences Limited

Financial Performance for Q1 FY27

11th August, 2026, Ahmedabad, India

Q1 FY27 Key Financial Highlights

Q1 FY27 Highlights

- Revenue from operations at Rs. 80,170 mn, up 22% over last year.
- R&D investments for the quarter stood at Rs. 6,424 mn (8% of revenues).
- EBITDA for the quarter was Rs. 19,294 mn, down 8% y-o-y. EBITDA margin for the quarter stood at 24.1%.
- Net Profit for the quarter was Rs. 9,398 mn, down 36% y-o-y.
- Capex (organic) for the quarter was Rs. 5,852 mn.
- Net Debt to Equity ratio as on 30th June 2026 was 0.22x while Net Debt to EBITDA stood at 0.70x at the end of June 2026.

Q1 FY27 Consolidated Financial Results

Rs. Mn	Q1 FY27	Q1 FY26	% Gr. YoY	Q4 FY26	% Gr. QoQ
Revenue from operations	80,170	65,737	22.0%	75,870	5.7%
EBITDA	19,294	20,885	-7.6%	25,544	-24.5%
EBITDA margin (%)	24.1%	31.8%		33.7%	
PBT	13,066	19,206	-32.0%	16,597	-21.3%
Net Profit	9,398	14,668	-35.9%	12,725	-26.1%

FY27 is off to a strong, profitable start. We continue advancing into an innovation-led, patient-centric organization. Our branded portfolio now exceeds 55% of revenues. Notably, the share of branded sales in the US reached 11% and will continue to expand with the upcoming Saroglitazar launch. Backed by diverse manufacturing and robust quality systems, we will further strengthen our core businesses and expand our market share. Driven by execution rigor and acquisition synergies, we are well-positioned for our next growth phase.

Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878






Dedicated To Life


Q1 FY27 Business-wise Sales Performance (Consolidated)

Rs. Mn	Q1 FY27	Q1 FY26	% Gr. YoY	Q4 FY26	% Gr. QoQ
Pharma Business	60,900	56,101	8.6%	56,436	7.9%
India Formulations	18,158	15,192	19.5%	17,528	3.6%
North America Formulations	30,979	31,817	-2.6%	29,523	4.9%
IM Formulations	9,735	7,265	34.0%	8,041	21.1%
APIs	1,804	1,575	14.5%	1,219	48.0%
Alliances & Others	224	252	-11.1%	125	79.2%
Consumer Wellness	14,292	8,549	67.2%	14,633	-2.3%
MedTech	2,828	20		3,275	-13.6%
Consolidated Revenues	78,020	64,670	20.6%	74,344	4.9%

Q1 FY27 Consolidated business mix



Q1 FY27 Pharma business mix



Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Q1 FY27 Business Updates

Pharma Business

India Formulations business

- Registered revenues of Rs. 18,158 mn, up 20% y-o-y. The business accounted for 23% of consolidated revenues.
- The business has consistently outperformed IPM growth over the last 3 financial years.
- Growth during the quarter was broad based as the business grew faster than the market in super-specialty, chronic and acute segments.
- In terms of therapeutic performance, outpaced IPM growth in key therapies of Cardiology, Diabetology, Gynaecology, Anti-infectives, Pain Management and in super specialty areas of Oncology and Nephrology.
- Ranking improved in key therapies of Cardiology, Diabetology and Pain Management while on the super specialty front, retained leadership position in Oncology segment.
- Large innovative brands led by Lipaglyn® continue to strengthen their market standing and improve their rankings quarter after quarter, underscoring the impact of innovation on improved patient outcomes.
- Share of chronic and sub chronic portfolio has increased consistently over last several years and stood at 54.2%, an improvement of 360 bps over the last 4 years (Source: AWACS MAT June 2026 data).

North America formulations business

- Registered revenues of Rs. 30,979 mn, down 3% y-o-y and up 5% q-o-q. The business accounted for 40% of consolidated revenues.
- In constant currency terms, the business registered revenues of US\$ 327 mn.
- US base business continued to gain market share driven by sustained volume expansion supplemented by new products launches.
- In the US generics space, filed 5 ANDAs, received approval for 9 ANDAs (including 4 tentative approvals) and launched 11 new products during the quarter.

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

- On the US specialty front,
 - Launched NUFYMCO™ (Ranibizumab) injection, the company's first biosimilar in the US market.
 - Completed the acquisition of Assertio Holdings, significantly strengthening presence in the US specialty space.
- In Canada, received 2 ANDS approvals and launched 2 new products during the quarter.

International Markets formulations business

- Registered revenues of Rs. 9,735 mn, up 34% y-o-y. The business accounted for 12% of consolidated revenues.
- Growth was led by strong demand-driven performance across markets and supported by focused execution.

API business

- Registered revenues of Rs. 1,804 mn, up 15% y-o-y. The business accounted for 2% of consolidated revenues.

Alliances & Others

- Registered revenues of Rs. 224 mn, down 11% y-o-y. The business accounted for 0.3% of consolidated revenues.

Consumer Wellness business

- Registered revenues of Rs. 14,292 mn, up 67% y-o-y. The business accounted for 18% of consolidated revenues.
- Domestic business grew 5% y-o-y. Skin & hair care brands and food & nutrition brands registered 35% and 16% y-o-y growth respectively. Seasonal brands, however, de-grew primarily due to the softer summer season.
- International business, including the Comfort Click business, delivered 25% growth on a like-to-like basis.

MedTech business

- Registered revenues of Rs. 2,828 mn. The business accounted for 4% of consolidated revenues.
- The company is investing in enhancing its capabilities in focused therapies which offer long-term growth potential to create differentiated value.

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Updates on Operations and Compliance

- Injectable manufacturing facility at Zydus Biotech Park received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification following a GMP surveillance inspection conducted in April-May 2026.

Updates on Innovation Pipeline

NCE Research

- The USFDA granted priority review to the New drug Application (NDA) of Saroglitazar Magnesium for the treatment of Primary Biliary Cholangitis (PBC).
- Received regulatory approval in India to initiate Phase III clinical trials of Desidustat in patients with sickle cell disease.

Biotech R&D

- Initiated Phase III clinical trials in India for the second biosimilar antibody drug conjugate.

Vaccines R&D

- Completed Phase II clinical trials of bivalent Typhoid Conjugate vaccine and initiated Phase I clinical trials of Chikungunya vaccine in India.
- On the global development front, submitted the dossier of Measles and Rubella (MR) vaccine to World Health Organization (WHO). The dossier has been accepted for review.

Other Updates

- Entered into a joint venture agreement with Sunshine Healthcare Lanka Limited to establish a pharmaceutical manufacturing facility in Sri Lanka to strengthen local production and reduce import dependence for the country.

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Q1 FY27 Earnings Call Details

The Company will host its post results earnings call at **4:00 p.m. IST on 11th August, 2026** during which the leadership team will discuss the financial performance and address questions from the participants.

A transcript of the conference call will be available at the Company's website: <https://www.zyduslife.com/investorzone>

To join the call through Zoom:

Please pre-register by clicking here: <https://bit.ly/4w2juWX>

About Zydus Lifesciences Limited

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com.

For further information, please contact -

Investors:

Mr. Arvind Bothra

Email: Arvind.bothra@zyduslife.com

Phone: +91-79-48040969

Media:

Ms. Sujatha Rajesh

Email: Sujatha.rajesh@zyduslife.com

Phone: +91-79-48040353

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

